MAGE-A3 Antigen-Specific Cancer Immunotherapeutic in Patients With Progressive Metastatic Cutaneous Melanoma

Summary

This study is being done to evaluate the safety and the clinical activity of MAGE-A3 Antigen-Specific Cancer Immunotherapeutic in patients with unresectable and progressive metastatic cutaneous melanoma.

Timeline

Start

2008-09-29

Primary completion

2011-01-19

Completion

2011-01-19

Outcome

Outcome not reported

Stopped (Enrollment): “The study was terminated early due to difficulties in recruiting subjects, not following concerns for the safety or absence of clinical activity in patients.”

Drugs

Indications